ArticleMedicine2026
Enhanced recovery after surgery for microsurgical oblique lateral interbody fusion: A retrospective before-and-after cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluates the real-world effectiveness and safety of a standardized enhanced recovery after surgery (ERAS) pathway in patients undergoing single-level microsurgical oblique lateral interbody fusion (MIS-OLIF) for lumbar degenerative disease. This retrospective before-and-after cohort study included 89 patients who underwent single-level MIS-OLIF at L3-4 or L4-5 between January 2021 and December 2023. Patients were categorized according to the institutional perioperative pathway in effect at the time of surgery: conventional care (n = 44) or ERAS (n = 45). The primary outcome was postoperative length of stay. Secondary outcomes included back-pain and leg-pain visual analog scale (VAS) scores, Oswestry Disability Index (ODI), ERAS-component adherence, discharge readiness, complications, readmission, and patient satisfaction. Selection bias was addressed using propensity-score overlap weighting, and repeated VAS and ODI measurements were analyzed using linear mixed-effects models. The ERAS group had a shorter unadjusted hospital stay than the conventional-care group (6.2 ± 0.8 vs 7.5 ± 1.2 days). After overlap-weighting adjustment, ERAS was associated with an adjusted reduction in postoperative length of stay of -1.1 days (95% confidence interval [CI]: -1.4 to -0.8; P < .001). Early postoperative back and leg pain were significantly lower in the ERAS group (group-by-time interaction P = .02 and P = .04, respectively). Overall ERAS adherence was 94.7% (median). Complication rates were 11.1% vs 18.2% (adjusted odds ratio 0.52, 95% CI: 0.14-1.94, P = .33), and satisfaction rates (satisfied/very satisfied) were 97.8% vs 93.2% (P = .36). In this single-center real-world cohort, implementation of a standardized ERAS pathway was associated with earlier discharge after single-level MIS-OLIF. The effects on pain, function, satisfaction, and safety should be interpreted according to the adjusted analyses and remain subject to residual confounding inherent in the retrospective before-and-after design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.